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Type 2 diabetes mellitus (T2DM) is a polygenetic disease. Its incidence is increasing continuously in Taiwan as the 
standard of living improves. Current diabetes research is striving to identify those high at risk of T2DM through T2DM-
associated gene studies. A number of techniques are available for the molecular detection of T2DM-associated genes, 
including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), direct sequencing, and 
TaqMan genotyping. However, they are capable of analyzing only one molecular target in each experiment. In the 
present study, we selected eight candidate genes that are potentially associated with T2DM [angiotensinogen (AGT), 
sulfonylurea receptor-1 (SUR-1), peroxisome proliferators-activated receptor-γ (PPAR-γ), PPAR-γ coactivator-1 (PGC-1), 
calpain-10 (CAPN10), β2-adrenergic receptor (ADRB2), mannose-binding lectin (MBL2), and insulin receptor substrate-1 
(IRS-1)]. We used enzymatic chip array technology, which we had previously established, and analyzed its relevance 
to diabetes research. We enrolled 1280 Taiwanese patients (700 with T2DM and 580 non-diabetic controls). The genes 
of all subjects were analyzed by the enzymatic chip array. The results were consistent with direct sequencing. On the 
basis of multivariate logistic-regression analysis—with adjustment for age—the following variables were associated with 
a significant risk of T2DM: body mass index, serum cholesterol, triglyceride level, low- and high-density lipoprotein 
cholesterol levels, and polymorphisms, including PGC-1 Gly482Ser, SUR1 Arg1273Arg, ADRB2 Arg16Gly, CAPN10 SNP43, 
AGT Met235Thr, and MLB2 Gly54Asp. The enzymatic chip array is a useful tool for multiple gene analysis in diabetes.
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Introduction
Diabetes mellitus type 2 (T2DM) is a complex multi-
factorial and polygenetic disorder in which environ-
mental triggers interact with genetic components 
to lead to disease predisposition.1 T2DM creates a 
great deal of human suffering and is a significant fi-
nancial burden worldwide. One approach to prevent 
this condition is to identify disease-susceptibility 
genes. In addition to providing important etiolog ical 
insights, identifying risk alleles could help clarify 
which groups of people have a high or low risk of 
developing T2DM.
Two methods have been used to detect genetic 
polymorphisms associated with T2DM. One makes 
use of genome-wide scans—more than 50 such scans 
have been completed in a variety of ethnic groups.2 
However, these results revealed no single global 
linkage signal for T2DM. The limitations of genome-
wide scans are widely accepted for conditions with 
multifactorial traits.3 The other method used is 
T2DM-related genetic polymorphism association 
studies, which identify several T2DM-associated 
genes. A number of techniques are available for the 
molecular detection of T2DM-associated genes, in-
cluding polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP), direct 
sequencing, and TaqMan genotyping.4−6 Applying 
PCR-RFLP and direct sequencing to detect multiple 
genes would be time-consuming and laborious 
in clinical practice. TaqMan genotyping, molecular 
beacons, and invader assays perform rapid single 
nucleotide polymorphism (SNP) analysis,4 but the 
use of fluorescence as a signal indicator makes these 
assays very expensive. Although these methods pro-
vide useful data, they are limited by only being able 
to analyze one molecular target in each experiment. 
Therefore, a robust assay is required, using a high 
sensitivity and high throughput method that is 
capable of detecting T2DM genes by using a panel 
of informative molecular markers simultaneously. 
In the present study, we used the enzymatic chip 
array, previously established in our laboratory,7,8 
as the technological platform for detecting T2DM-
associated genes.
By using public databases, including PubMed 
and Online Mendelian Inheritance in Man, we se-
lected eight candidate genes and nine character-
ized polymorphisms (Table 1) that are potentially 
associated with T2DM [genes selected: angiotensino-
gen (AGT), sulfonylurea receptor-1 (SUR-1), peroxi-
some proliferators-activated receptor-γ (PPAR-γ), 
PPAR-γ coactivator-1 (PGC-1), calpain-10 (CAPN10), 
β2-adrenergic receptor (ADRB2), mannose-binding 
lectin (MBL2), and insulin receptor substrate-1 
(IRS-1)]. Because of genetic racial/ethnic differ-
ences, it is important to construct a database of 
genes related to T2DM in each racial/ethnic 
group.
This study explored a high-sensitivity and high-
throughput technology to investigate the risk genes 
related to T2DM in Taiwan. In future research, we 
hope that these genes can be used in conjunction 
with preventive medicine in order decrease the 
incidence of T2DM.
Materials and Methods
Study population
Seven hundred patients with T2DM were included 
in this study—they were enrolled from Fooyin 
University Hospital, Pingtung Christian Hospital, 
and Kaohsiung Medical University Hospital between 
January 2005 and December 2007. T2DM was di-
agnosed using the American Diabetes Association 
(1997) criteria. Non-diabetic controls were recruited 
from a pool of individuals who had a general health 
evaluation at the Fooyin University Hospital, 
Pingtung Christian Hospital, and Kaohsiung Medical 
University Hospital. The hospital’s Human Research 
Ethics Committee approved the study design, and 
informed consent was obtained from all participants. 
T2DM patients received a complete physical exam-
ination, as well as an assessment for the presence 
and extent of macro- or microvascular complica-
tions. Routine blood and urine analyses were per-
formed. Measurements were also taken to calculate 
the body mass index (BMI).
Enzymatic chip array preparation
We used OMP3 to design oligonucleotides of candi-
date genes. There were four oligonucleotides (two 
allele specific oligo and two mutant control oligo 
Table 1  Type 2 diabetes-associated genetic polymor-
phisms examined in this study
Gene Polymorphism
Angiotensinogen (AGT) Met235Thr
Sulfonylurea receptor-1 (SUR-1) Arg1273Arg
Peroxisome proliferators-activated  Pro12Ala
 receptor-γ (PPAR-γ)
PPAR-γ coactivator-1α (PGC-1) Gly482Ser
Calpain-10 (CAPN10) SNP-43
β2-adrenergic receptor (ADRB2) Arg16Gly
 Gln27Glu
Mannose-binding lectin (MBL2) Gly54Asp
Insulin receptor substrate-1 (IRS-1) Gly972Arg
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probes) for each polymorphism (Table 2). The newly 
synthesized oligonucleotides were dissolved in di-
water to a concentration of 20 mM and then placed 
inside a BioJet Plus 3000 nanoliter dispensing sys-
tem (BioDot Inc., Irvine, CA, USA), which sequen-
tially blotted the target DNA on a SuPerCharge nylon 
membrane (Schleicher & Schuell, Dassel, Germany). 
After being air-dried and UV cross-linked, the mem-
branes were heated at 80°C for 2 hours and stored in 
a desiccator at room temperature for up to 2 weeks.
Genotyping of polymorphisms
DNA isolation and digoxigenin-labeled DNA
Genomic DNA was extracted from peripheral blood 
leukocytes using either QIAamp mini kits (Qiagen 
Inc., Valencia, CA, USA) or Generation Capture 
Column kits (Gentra Systems Inc., Minneapolis, 
MN, USA). Polymorphic regions of each gene were 
amplified by multiple PCRs with two allele-specific 
sense (or anti-sense) primers (Table 3). The reaction 
Table 2 Oligonucleotide sequences of type 2 diabetes-associated single nucleotide polymorphisms
Gene Oligo Sequence Temperature (°C)
PGC-1 ASO − A allele ACGACGAAGCAGACAAGACCAGTGAACT 63.3
 MCO ACGACGAAGTAGACAAGACCAGTGAACT 58.9
Gly482Ser ASO − G allele CGACGAAGCAGACAAGACCGGTGAAC 65.5
 MCO CGACGAAGTAGACAAGACCGGTGAAC 61.0
ADRB2 ASO − A allele CTTCTTGCTGGCACCCAATAGAAGCC 63.8
 MCO CTTCTTACTGGCACCCAATAGAAGCC 59.5
Arg16Gly ASO − G allele CTTCTTGCTGGCACCCAATGGAAGC 65.4
 MCO CTTCTTACTGGCACCCAATGGAAGC 60.9
SUR-1 ASO − G allele CTCCAACTCCCTGCACAGGGAGCTC 65.0
 MCO CTCTAACTCCCTGCACAGGGAGCTC 60.6
Arg1273Arg ASO − A allele TCTCCAACTCCCTGCACAGAGAGCTC 63.0
 MCO TCTCTAACTCCCTGCACAGAGAGCTC 58.5
ADRB2 ASO − C allele ACCACGACGTCACGCAGCAAAGG 64.9
 MCO ACCACTACGTCACGCAGCAAAGG 60.1
Gln27Glu ASO − G allele ACCACGACGTCACGCAGGAAAGG 63.9
 MCO ACCACTACGTCACGCAGGAAAGG 59.1
AGT ASO − T allele AAGACTGGCTGCTCCCTGATGGGAG 64.5
 MCO AAGACTGTCTGCTCCCTGATGGGAG 60.8
Met235Thr ASO − C allele AAGACTGGCTGCTCCCTGACGGG 64.4
 MCO AAGACTGTCTGCTCCCTGACGGG 60.5
CAPN10 ASO − G allele GCTTGCTGTGAAGTAAGGCGTTTGAAGG 64.7
 MCO GCTTACTGTGAAGTAAGGCGTTTGAAGG 60.7
SNP43 ASO − A allele GCTTGCTGTGAAGTAAGGCATTTGAAGG 63.0
 MCO GCTTACTGTGAAGTAAGGCATTTGAAGG 58.9
IRS1 ASO − A allele GCCCTGCACCTCCCAGGGCT 64.1
 MCO GCCCTACACCTCCCAGGGCT 58.9
Gly972Arg ASO − G allele CCCTGCACCTCCCGGGGCT 64.9
 MCO CCCTACACCTCCCGGGGCT 59.6
PPAR-γ ASO − C allele AGAGATGCCATTCTGGCCCACCA 63.4
 MCO AGAGATACCATTCTGGCCCACCA 58.4
Pro12Ala ASO − G allele AGAGATGCCATTCTGGGCCACCA 63.4
 MCO AGAGATACCATTCTGGGCCACCA 58.4
MBL2 ASO − A allele GCAAAGATGGGCGTGATGACACCA 64.5
 MCO GCAAAGATAGGCGTGATGACACCA 59.9
Gly54Asp ASO − G allele CAAAGATGGGCGTGATGGCACCA  65.4
 MCO CAAAGATAGGCGTGATGGCACCA 60.6
ASO: allele-specific oligonucleotide; MCO: mutant control oligonucleotide; AGT: angiotensinogen; SUR-1: sulfonylurea receptor-1; 
PPAR-γ: peroxisome proliferators-activated receptor-γ; PGC-1: PPAR-γ coactivator-1; CAPN10: calpain-10; ADRB2: β2-adrenergic 
receptor; MBL2: mannose-binding lectin; IRS1: insulin receptor substrate-1.
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mixture contained 20 ng of DNA, 5 pmol of each 
primer, 2 μL 20 mM of dNTP, 2 μL 30 mM of MgCl2, 
4 μL of nuclease-free water, and 2 μL1U/μL of poly-
merase. Next, PCR products were labeled with 
dTTP: DIG-11-dUTP (Roche Diagnostics, Laval, QC, 
Canada) as the last step of synthesis. The labeling 
reaction was carried out at 37°C for 20 hours and 
then ceased at 70°C for 10 minutes. The mixture 
of probes was denatured at 90°C for 10 minutes 
prior to hybridization.
Hybridization and data analysis of 
colorimetric membrane
The membrane was pre-hybridized and blocked be-
fore hybridization. The lifts were incubated with the 
ExpressHyb Hybridization Solution (BD Biosciences, 
Palo Alto, CA, USA) containing DIG-labeled SNP-
specific library (at 48°C for 12 hours in a humid 
chamber). After washing, the membrane was incu-
bated with an alkaline phosphatase-conjugated anti-
digoxigenin antibody (Roche Diagnostics) at 37°C for 
1 hour. After removing unbound antibodies by exten-
sive washing, the membrane was incubated in chro-
mogen solution containing nitroblue-tetrazolium and 
5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP) for 
15 minutes for color development. The membrane 
was dried at 60°C, then scanned with an Epson 
Perfection 1670 flatbed scanner (Seiko Epson Corp., 
Nagano, Japan). Homozygous and heterozygous SNP 
genes on the membrane were determined by the 
development of substrate color.
To confirm the accuracy of genotyping, we ran-
domly selected 50 DNA samples and subjected them 
to direct DNA sequencing of the PCR products. 
In each instance, the genotype determined by 
the membrane assay system was identical to that 
determined by the confirmatory methods.
Direct sequencing of genes
Sequencing analysis was performed to confirm the 
following genes by membrane assay: AGT Met235Thr, 
PGC-1 Gly482Ser, SUR1 Arg1273Arg, CAPN10 SNP43, 
IRS1 Gly972Arg, PPARγ Pro12Ala, MBL2 Gly54Asp, 
ADRB2 Arg16Gly, and Gln27Glu. The PCR amplifica-
tion of DNA samples was performed within a 50 μL 
vessel containing 34 μL of H2O, 2 μL of genomic DNA, 
5 μL of 10X PCR buffer, 5 μL of dNTP mixture (2.5 mM), 
2 μL of primers mixture (20 μM), and 2 μL of Taq 
polymerase (5 U). Reactions were conducted in a pro-
grammable thermal cycler (PTC-100; MJ Research, 
Watertown, MA, USA) under the following condi-
tions: 30 denaturing cycles for 30 seconds at 95°C, 
annealing for 6 seconds at 71°C, and extension for 
30 seconds at 72°C. The PCR products were puri-
fied by the QIAEX II Gel Extraction Kit (Qiagen Inc.) 
and then subjected to sequencing. The sequences 
were analyzed by Protech Technology Enterprise 
Co. Ltd. (Taipei, Taiwan).
Table 3 Polymerase chain reaction primers for type 2 diabetes-associated genes
Gene SNP Primer sequence
PGC-1  Gly482Ser Sense CGAGCTGAACAAGCACTTCGGTCA
  Antisense  GGCCATCCATGGCTAGTCCTGAATT
ADRB2 Arg16Gly Sense CGAGTCCCCACCACACCCACA
  Antisense  TCCCTTTCCTGCGTGACGTCGT
SUR-1 Arg1273Arg Sense GGTAGAACAGGGGCCTGTGGCTCTA
  Antisense  GTCTCCAGTGACGAAGGTGCTCCG
ADRB2 Gln27Glu Sense ACCCACACCACAGCCGCTGAAT
  Antisense  CCCAAAGGGCACCACTGCCA
AGT Met235Thr Sense AAGATTGACAGGTTCATGCAGGCTG
  Antisense  TAGGTGTTGAAAGCCAGGGTGCTGT
CAPN10 SNP43 Sense TGTGTGTGGGCAGAGGACTGCA
  Antisense  CTCTGCCTTCTTCCTCATCCTCACC
IRS1 Gly972Arg Sense GAGTACATGAAGATGGACCTGGGGC
  Antisense  GACGGGGACAACTCATCTGCATG
PPAR-γ Pro12Ala Sense GAGCGCCCAGATGAGATTACTTTGC
  Antisense  GGGCTTGATATCAAAGGAGTGGGAG
MBL2 Gly54Asp Sense ACCATGTCCCTGTTTCCATCACTCC
  Antisense  CATCAGTCTCCTCATATCCCCAGGC
PGC-1: PPAR-γ coactivator-1; ADRB2: β2-adrenergic receptor; SUR-1: sulfonylurea receptor-1; AGT: angiotensinogen; CAPN10: calpain-10; 
IRS1: insulin receptor substrate-1; PPAR-γ: peroxisome proliferators-activated receptor-γ; MBL2: mannose-binding lectin.
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Biochemical analyses
We measured total cholesterol (TC) and triglyceride 
(TG) levels with a biochemical analyzer (SYNCHRON 
CX-5CE; Beckman Coulter Inc., Fullerton, CA, USA). 
The TC and TG levels were analyzed using the 
CHOD-POD method and the Lipase-GOD-POD method 
(Beckman Reagent Kit; Beckman Coulter Inc.), re-
spectively. The high-density lipoprotein-cholesterol 
(HDL-C) and low-density lipoprotein-cholesterol 
(LDL-C) fractions were measured using an electro-
phoresis analyzer (Helena REP; Helena Laboratories, 
Beaumont, TX, USA). 
Statistical analysis
The clinical and biochemical features of the popu-
lation are presented as mean ± standard deviation. 
Odds ratios and 95% confidence intervals were de-
termined to assess the genetic differences between 
the two groups. The observed frequencies of the 
genes were compared using the Hardy-Weinberg 
equilibrium by χ2 tests.9 Student’s t tests were used 
to detect mean differences in biochemical data. All 
p values were calculated based on two-sided tests 
with statistical significance defined as p < 0.05.
Results
Table 4 lists the characteristics of controls and 
T2DM patients. Age distribution was not significantly 
different between the two groups. According to ran-
dom selection criterion, as was expected, the dia-
betic patients had higher BMI, higher systolic blood 
pressure, higher serum cholesterol, and higher TG 
and LDL-C levels compared with controls. In addi-
tion, the serum HDL-C level was significantly lower 
in T2DM patients.
Figure 1 shows the reaction doctrine of the oligo-
enzymatic chip array. On the established enzymatic 
chip array, each oligo probe encodes in double rep-
etition. A mutant control oligonucleotide (MCO) was 
designed for each allele-specific oligonucleotide 
(ASO). There was only one nucleotide difference 
between the MCO and the ASO. A DNA fragment that 
can be hybridized with allele-specific oligo probes, 
but not with mutant control oligo probes, is con-
sidered true positive, and a positive hybridization 
turns blue−purple after color fixatives are added. 
Therefore, after comparison with the C allele results, 
one test was identified as a TT genotype sample 
(Figure 1).
The enzymatic chip array was confirmed with 
direct sequencing by randomly selecting 50 DNA 
samples and subjects. The accuracy of genotyping 
by the enzymatic chip array method was consistent 
with the results of direct sequencing (Figure 2). 
Figure 2A shows the genes of one subject by direct 
sequencing [PGC1 Gly482Ser (AG), SUR1 Arg1273Arg 
(GG), AGT Met235Thr (CC), ADRB2 Arg16Gly (GA), 
and CAPN10 SNP43 (GG)]. The same DNA sample 
was applied to the enzymatic chip array system, 
Table 4 Characteristics of normal controls and type 2 diabetes patients*
 
Controls (n = 580) Patients with type 2 p
  diabetes (n = 700)
Age (yr) 61.32 ± 9.32 60.73 ± 11.56 0.942
BMI 23.51 ± 2.95 24.93 ± 2.66 < 0.0001
SBP (mmHg) 126.57 ± 14.30 128.15 ± 14.62 0.0005
DBP (mmHg) 77.47 ± 10.58 78.06 ± 8.66 0.072
Chol (mg/dL) 168.74 ± 28.90 223.6 ± 45.79 < 0.0001
TG (mg/dL) 89.55 ± 55.64 183.91 ± 87.54 < 0.0001
LDL-C (mg/dL) 109.65 ± 28.29 136.63 ± 87.26 < 0.0001
HDL-C (mg/dL) 56.49 ± 11.59 43.56 ± 24.45 < 0.0001
*Data presented as mean ± standard deviation. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; 
Chol: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol.
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Figure 1 Genotyping with the enzymatic chip array 
method.
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which revealed results identical to those of direct 
sequencing.
Figure 3 shows the genes of another subject 
[PGC1 Gly482Ser (AG), SUR1 Arg1273Arg (GG), 
AGT Met235Thr (CT), ADRB2 Arg16Gly (AA), ADRB2 
Gln27Glu (CC), IRS1 Gly972Arg (AG), PPAR-γ Pro12Ala 
(CC), MBL2 Gly54Asp (AG), and CAPN10 SNP43 (GG)]. 
Identification was based on the membrane substrate 
color (blue−purple). The membrane assay method 
was performed with simple devices and materials 
according to standard procedures.
On the basis of multivariate logistic-regression 
analysis—with adjustment for age—the following 
variables were associated with a significant risk of 
T2DM: BMI, serum cholesterol, TG, LDL-C/HDL-C lev-
els, and polymorphisms, including PGC-1 Gly482Ser, 
SUR1 Arg1273Arg, ADRB2 Arg16Gly, CAPN10 SNP43, 
AGT Met235Thr, and MLB2 Gly54Asp (Table 5). All 
genotypic distributions were examined assuming the 
Hardy-Weinberg equilibrium.
Discussion
Molecular detection of T2DM genes by PCR-RFLP and 
direct sequencing has been used increasingly in the 
last decade. However, applying PCR-RFLP and direct 
sequencing for the detection of multiple genes would 
be too time-consuming for clinical practice. In the 
present study, we used an enzymatic chip array 
method, which not only accurately detected multi-
ple genetic polymorphisms simultaneously, but also 
used a simple set of devices and materials, and used 
simple procedures. Both the difficulty and cost of the 
experiment were relatively minimal. Therefore, this 
technique has merit and should be considered for 
A B
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Figure 2 Type 2 diabetes-associated genes from one subject. A comparison of: (A) direct sequencing; (B) enzymatic 
chip array method.
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Figure 3 Genes of one subject identified 
based on the substrate color (blue−purple) 
from the enzymatic chip array.
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detecting polymorphisms of candidate genes asso-
ciated with polygenetic diseases including T2DM.
T2DM is a polygenetic disease. Thus, simulta-
neous detection of multiple genetic polymorphisms 
is required. Racial and ethnic differences in genetic 
polymorphisms exist, and it is vital to construct a 
database of T2DM-associated genes for each racial 
and ethnic group. In this study, we examined nine 
polymorphisms in nine candidate genes in 1,006 
Taiwanese patients and controls. The results re-
vealed that certain polymorphisms were associ-
ated with a significant risk of T2DM in Taiwanese 
people (PGC-1 Gly482Ser, SUR1 Arg1273Arg, ADRB2 
Arg16Gly, CAPN10 SNP43, AGT Met235Thr, and MLB2 
Gly54Asp).
A meta-analysis showed that the PGC-1 Gly482Ser 
polymorphism is associated with T2DM in a Caucasian 
population.10 Other studies11,12 have revealed that 
PGC-1 Gly482Ser polymorphisms are not associated 
with T2DM. Recently, this polymorphism was re-
ported to be a predictor for the conversion from 
impaired glucose tolerance to T2DM.13 Our results 
suggest that the AA genotype PGC-1 Gly482Ser 
polymorphism is a risk factor for T2DM in the 
Taiwanese population.
The AGT Met235Thr gene polymorphism was re-
ported to not be associated with diabetes in 400 
Taiwanese persons (including diabetes patients).14 
AGT plays a role in regulating the growth and dif-
ferentiation of adipose tissue,15 and AGT synthesis 
in the liver is regulated by insulin, so it is likely 
that AGT may affect insulin resistance.16,17 Guo 
et al18 found that the Thr allele of AGT M235T was 
significantly associated with increased insulin 
resistance in Mexican Americans. Takakura et al19 
reported that the CC genotype of AGT Met235Thr 
gene polymorphism was linked to visceral obesity 
and insulin resistance in Japanese women. The results 
of our analyses suggest that the CC genotype is a 
risk factor for T2DM.
ADRB2 Arg16Gly and Gln27Glu gene polymor-
phisms are associated with T2DM.20−22 One study 
of a Taiwanese population23 revealed that ADRB2 
Arg16Gly, but not Gln27Glu, was associated with 
T2DM. Our results suggest that the Arg genotype of 
the ADRB2 Arg16Gly gene is a risk factor for T2DM, 
a view consistent with the latter observation.
The MLB2 Gly54Asp gene polymorphism was as-
sociated with gestational diabetes mellitus in a 
population from Spain.24 MBL is a plasma protein 
synthesized in the liver and released as a component 
of the acute-phase response.25 MBL may aggravate 
local and systemic inflammation through comple-
ment activation26,27 and modulation of proinflam-
matory cytokine production.28 Inverse correlations 
between indexes of insulin sensitivity and serum 
markers of inflammation have been found.29,30 Our 
results suggest that the MLB2 Gly54Asp gene poly-
morphism is a risk factor for T2DM.
The CAPN10 gene is the first T2DM candidate 
gene identified through genome-wide linkage and 
positional cloning.31 Horikawa et al first reported 
that G allele homozygosity in UCSNP-43 was asso-
ciated with T2DM. One meta-analysis32 confirmed 
that individuals who are homozygous for the G al-
lele had a 19% increased risk of T2DM. Our results 
suggest that homozygosity of the G allele in 
UCSNP-43 of CAPN10 gene polymorphism is a risk 
factor for T2DM.
The SUR1 Arg1273Arg polymorphism was associ-
ated with high insulin concentrations in normal in-
dividuals from an ethnic group with a high risk for 
diabetes.33 Reis et al34 showed that this polymor-
phism is associated with T2DM in French Caucasians. 
Recently, the SUR1 Arg1273Arg polymorphism was 
shown to be associated with T2DM in Finnish sub-
jects.35 Our study suggests that AA and AG genes 
are risk factors for T2DM.
T2DM involves the interplay of several candidate 
genes. The enzymatic chip array method used here 
was designed to quickly screen a large number of 
genes with preselected polymorphisms, based on the 
current literature. This method limits the numbers 
of polymorphisms in each gene and may decrease 
the ability to detect their effects, even if they are 
important. However, the polymorphisms tested in 
Table 5 Multivariate logistic regression analyses of various genetic polymorphisms associated with type 2 diabetes*
Gene SNP Risk genotype OR 95% CI p
PGC-1 Gly482Ser AA/AG vs. GG 1.889 1.349−2.648 < 0.0001
SUR-1 Arg1273Arg AA/AG vs. GG 2.217 1.582−3.107 < 0.0001
AGT Met235Thr CC/CT vs. TT 1.721 1.217−2.436 0.002
ADRB2 Arg16Gly AA vs. GG/GA 2.196 1.528−3.156 < 0.0001
CAPN10 SNP-43 GG vs. GC/CC 1.990 1.426−2.897 < 0.0001
MBL2 Gly54Asp AA/AG vs. GG 1.891 1.347−2.656 < 0.0001
*Logistic regression analyses adjusted for age, BMI, serum cholesterol, TG, LDL-C and HDL-C levels. SNP: single nucleotide polymorphism; 
OR: odds ratio; CI: confidence interval; PGC-1: peroxisome proliferators-activated receptor-γ coactivator-1; SUR-1: sulfonylurea 
receptor-1; AGT: angiotensinogen; ADRB2: β2-adrenergic receptor; CAPN10: calpain-10; MBL2: mannose-binding lectin; BMI: body 
mass index; TG: triglyceride; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol.
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this study were those specifically identified in pre-
vious reports. A possible limitation of this study is 
that a spurious association may arise from selection 
bias, population stratification, multiple hypothesis 
testing, subgroup analysis, and inadequate statisti-
cal power. In our study, 1006 subjects were recruited 
and statistical significance was found. Therefore, 
the statistical power was adequate. We character-
ized these polymorphisms in a homogeneous ethnic 
population from a restricted geographical area that 
had no recent immigration.
In conclusion, this study outlined the creation of 
the enzymatic chip array—a method performed with 
simple devices and materials with a straightforward 
procedure. It was designed to simultaneously detect 
multiple genetic polymorphisms of T2DM-associated 
genes. Determination of these genes (outlined above) 
may be useful in predicting the genetic risk of T2DM 
in the Taiwanese and other populations. Further 
research is required to elucidate the possible genetic 
mechanisms in T2DM, and to develop the application 
of our method to clinical practice.
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